About the Company
Mabscale, LLC is a biopharmaceutical company engaged in development and production of drugs (biosimilars) based on monoclonal antibodies and other recombinant proteins.
Company History
Mabscale has been founded in October 2017. In early December of the same year, the construction of a plant was started in the Special Economic Zone (SEZ) of Togliatti. The dynamic construction pace allowed to launch the production site in 2019.
Simultaneously with the plant construction, the company carried out laboratory developments of property biosimilar products. The first drug developed and manufactured by Mabscale, LLC is currently undergoing clinical trials; several products are at the stage of preclinical trials; some drugs are at the stage of in-house development with the involvement of leading institutions and companies in the global biopharmaceutical market.
Advantages
The production facilities of Mabscale, LLC allow not only the transfer of ready-made methods, but also for implementing a full production cycle of biotechnological drugs: from creating highly productive cell lines to industrial in-house production of APIs and FDFs. Currently, the prospective portfolio of Mabscale, LLC already includes 5 biosimilar products at different stages of clinical and preclinical trials, as well as several drugs at various stages of development and transfer.
Collaboration with industry-leading research institutions and biotech companies worldwide.
Compliance with international quality standards. An industrial complex with a surface area of more than 5 thousand sq.m. has been built taking into account all GMP requirements for the development, production, and storage of medicines obtained using the biotechnological method.
The tax preferences of the SEZ, in the territory of which Mabscale, LLC is located, allow reducing raw material costs and providing the plant with the state-of-the-art equipment while saving on the customs costs.
Partners
Our Team
Titova Natalya Anatolievna
CEO
Petrov Aleksandr Vladimirovich
Candidate of Medical Sciences, Deputy General Director for Development
